Clinical trials: open to volunteers, sponsored by Fudan University
Pancreatic Cancer Metastatic
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
This is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients.
- Trial name
- NCT07920731
- Testing
- imotuzumab combined with the NALIRIFOX chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
TNBC - Triple-Negative Breast Cancer
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
This is an open, randomized, controlled, multicenter Phase III clinical study. Eligible subjects were randomly assigned 1:1 to albumin-paclitaxel plus carboplatin and carrilizumab with or without famitinib neoadjuvant therapy.
- Trial name
- BCTOP-T-N01 (NCT05999149)
- Testing
- Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 424 people
- Sponsor
- Fudan University
Alzheimer's Disease (AD)
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
The goal of this multicenter retrospective observational study is to learn about the real-world safety and clinical effectiveness of disease-modifying therapy (DMT) in adults with mild cognitive impairment (MCI) due to…
- Trial name
- ROOT-AD (NCT07923812)
- Testing
- Disease-Modifying Therapy
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Fudan University
Triple-Negative Breast Cancer (TNBC), Brain Metastases
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab…
- Trial name
- BALISTA (NCT06793332)
- Testing
- Ivonescimab Combined With TROP2 ADC
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fudan University
Breast Cancer
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
- Trial name
- NCT07918079
- Testing
- Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET
- Volunteers
- 84 people
- Sponsor
- Fudan University
Colorectal Cancer Liver Metastases (CRLM), ctDNA
Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection
This is a prospective, randomized, controlled, multicenter phase II trial evaluating whether circulating tumor DNA (ctDNA) methylation-guided adjuvant therapy improves outcomes after R0 resection of colorectal cancer liver…
- Trial name
- LEGEND (NCT07917104)
- Testing
- Circulating Tumor DNA Methylation Testing, Conventional Postoperative Treatment Strategy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Fudan University
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
Background: Sinonasal adenoid cystic carcinoma (ACC) is a rare type of cancer that starts in the nasal cavity or sinuses. Although surgery can remove the tumor, doctors often recommend radiation therapy after surgery to reduce…
- Trial name
- SPARE-1st (NCT07563088)
- Testing
- Postoperative Radiotherapy, Observation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
China HEalthy Aging and Dementia Study (HEAD)
The China HEalthy Aging and Dementia (HEAD) study is a large-scale, community-based, multi-center prospective cohort study covering eastern, northern, southern, and central-western regions of China.
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
- Trial name
- NCT07912710
- Where
- 30 sites in China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Fudan University
Adenoid Cystic Carcinoma
Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma
T4 stage sinonasal adenoid cystic carcinoma (SNACC) is a rare but aggressive cancer in the nasal cavity and sinuses. These tumors often invade the skull base, eye socket, or brain covering (dura), making complete surgical removal…
- Trial name
- NAET4-SNACC (NCT07616141)
- Testing
- Anlotinib Hydrochloride, Epirubicin
- Where
- 5 sites in China
- Volunteers
- 76 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity/sinuses) who receive standard treatment: surgery followed by postoperative radiotherapy.
- Trial name
- SPORT-SNACC (NCT07652489)
- Testing
- Surgery
- Where
- 6 sites in China
- Volunteers
- 70 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
This single-center, dual-cohort, exploratory phase II trial evaluates the efficacy and safety of trastuzumab rezetecan (SHR-A1811), an anti-HER2 antibody-drug conjugate (ADC), with or without the anti-PD-L1 antibody adebrelimab…
- Trial name
- NCT07912957
- Testing
- Trastuzumab Rezetecan (SHR-A1811), Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fudan University
Dry Eye
a Novel siRNA Eyedrops for DED Treatment
A single-center, randomized, double-blind, placebo-controlled, cross-over clinical trial designed to evaluate the effectiveness and safety of a novel siRNA eye drops for the treatment of dry eye syndrome
- Trial name
- NCT07908251
- Testing
- Low dose Arm, High dose Arm
- Volunteers
- 30 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT).
- Trial name
- PROTECT (NCT07647029)
- Testing
- Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Fudan University
Breast Cancer Metastatic, Treatment Outcome
A Real World Study of Sacituzumab Govitecan
Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 negative Breast Cancer Patients
- Trial name
- NCT06966141
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Advanced HER2-positive Breast Cancer
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
This study is a randomized, open-label, controlled, multicenter Phase II trial conducted in patients with advanced HER2-positive breast cancer, aimed at evaluating the efficacy and safety of paclitaxel polymer micelles for…
- Trial name
- SPECTACLE (NCT07581795)
- Testing
- Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab, Taxanes combined with trastuzumab and pertuzumab.
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Breast Cancer, Bone Metastases
clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
This is a real-world study to explore the efficacy and safety of incadronate in the treatment of breast cancer patients with bone metastases.
- Trial name
- NCT06392217
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fudan University
Breast Cancer
Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
The goal of this observational study is to evaluate the feasibility and effectiveness of using non-contrast chest computed tomography scans for opportunistic breast cancer screening, and to further compare its diagnostic…
- Trial name
- OPBCS-CT (NCT07557654)
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Fudan University
Neonatal Congenital Heart Disease
Optimization of Two-Indicator Screening Protocol for Neonatal Congenital Heart Disease at High Altitude
This is a prospective observational screening study. First, researchers will optimize a two-indicator screening protocol for neonatal congenital heart disease (NCHD) adapted to high-altitude regions and evaluate its screening…
- Trial name
- NCT07901998
- Volunteers
- 6,300 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Fudan University
Cervical Cancer
Inactivated KAWAI Bacteria for Diarrhea Prevention During Pelvic Radiotherapy in Postoperative Cervical Cancer
This is a multicenter, randomized, double-blind, placebo-controlled study. The purpose of this study is to evaluate whether an oral probiotic supplement (KAWAI inactivated bacteria) can reduce the side effects (especially…
- Trial name
- NCT07900477
- Testing
- KAWAI powder
- Volunteers
- 100 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Puberty Changes
Indicators and Evaluation of Efficacy of Yin-nourishing and Fire-reducing Chinese Medicine for Girls With Rapid Progression of Early Puberty
1. Evaluate whether AMH and SHBG have differential expression before and after the diagnosis of rapid and slow progression types of early puberty and whether this difference has a predictive effect on the rapid progression type.
- Trial name
- NCT06820931
- Testing
- Xuandi Ziyin Mixture
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Children's Hospital of Fudan University